NYSE$CTEV
Claritev Corp · Q3 2025 earnings
Q3 2025 earnings · · Investor relations
Briefing
CTEV reported Q3 2025, revenue of $246M.
For Q3 2025, CTEV reported revenue of $246M. Management discusses operating trends, liquidity, and strategic priorities as disclosed in the quarterly filing.
- Revenue $246M.
- CTEV updated clinical, capital, or portfolio priorities in the filing.
- CTEV updated clinical, capital, or portfolio priorities in the filing.
Headline financials
Revenue & EPS history
Multiplan · Revenue · Quarterly
$246M
Forward guidance
Management discusses CTEV's outlook, capital deployment, and key risks as disclosed in the earnings materials and periodic report.
Tailwinds
- CTEV cited progress on strategic priorities in the quarterly filing.
- Liquidity and balance sheet support continued operations and investment.
Headwinds
- Macro, competitive, and regulatory factors may affect near-term results.
- R&D, credit, or project timing can create quarter-to-quarter volatility.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2025
-6.5%
Avg return
Earnings day
-5.1%
Avg return
5 days after
-3.8%
Avg return
30 days after
36%
9 / 25 earnings
Positive
+20.8%
Q1 2021
Best reaction
-32.8%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -8.8% | +7.7% | -2.6% | |
| Q4 2025 | -31.8% | -42.0% | -31.4% | |
| Q3 2025 | +11.8% | -5.4% | -45.2% | |
| Q1 2025 | +4.2% | +7.5% | +95.1% | |
| Q4 2024 | -32.8% | -28.1% | -24.8% | |
| Q3 2024 | -6.5% | -3.4% | -22.6% | |
| Q2 2024 | -23.9% | -10.2% | -47.8% | |
| Q1 2024 | +10.9% | -1.5% | -36.6% | |
| Q4 2023 | -0.9% | -13.4% | -27.6% | |
| Q3 2023 | -6.5% | -9.7% | -14.3% | |
| Q2 2023 | -8.9% | -14.0% | -17.8% | |
| Q1 2023 | -5.4% | +21.0% | +97.6% | |
| Q4 2022 | -10.2% | +10.0% | +6.0% | |
| Q3 2022 | -27.8% | -18.3% | -31.1% | |
| Q2 2022 | -12.4% | -13.4% | -33.1% | |
| Q1 2022 | +1.0% | +18.4% | +27.4% | |
| Q4 2021 | -8.0% | -18.9% | -14.4% | |
| Q3 2021 | +0.2% | -11.0% | -4.3% | |
| Q2 2021 | -6.2% | -10.5% | -20.6% | |
| Q1 2021 | +20.8% | +27.0% | +45.5% | |
| Q2 2020 | +0.5% | -0.2% | +1.9% | |
| Q4 2020 | -18.6% | -20.3% | -19.7% | |
| Q3 2020 | -4.6% | +0.7% | +20.8% | |
| Q1 2020 | +0.5% | +0.7% | +2.3% | |
| Q4 2019 | +0.5% | +0.7% | +2.3% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro